Sang Tae Park

Sang Tae Park serves as the Chief Executive Officer of Dx&Vx US since May 2023, leading the company's expansion into the US and other markets after a re-IPO. Additionally, Sang Tae Park holds board positions at OXFORD VACMEDIX UK LIMITED and Oxford Cancer Biomarkers, contributing to the development of cancer treatment technologies. As the CEO of COREE LLC, a subsidiary of Hanmi Pharmaceuticals, Sang Tae Park oversees research and business solutions, including maternal and child health initiatives. Previous roles include CEO and Chief Commercial Officer at Psomagen and CEO/Chief Technology Officer at Macrogen Clinical Laboratory, with substantial experience in genomic technologies and clinical diagnostics. Academic credentials include a Ph.D. in Molecular Microbiology from Yonsei University and a Drug and Medical Device Development executive program from MIT xPRO.